clinical trial · NCT07729371
A Safety Study of ST316 in Participants With Familial Adenomatous Polyposis (FAP).
Familial Adenomatous Polyposis (FAP)ST316 IVST316 IV
brief summary
This is a Phase 1b, open- label, dose-optimization study evaluating ST316 in adult participants with familial adenomatous polyposis (FAP) who have undergone colectomy and have recurrent polyps. This study uses a three-cohorts, sequential adaptive design to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of ST316, as well as its preliminary efficacy in reducing polyp recurrence.
started
Jan 4, 2027
primary completion
Dec 31, 2028
completion
Dec 31, 2029
last updated
Aug 12, 2026
official title
An Open-Label, Phase 1b Trial to Assess the Safety and Efficacy of ST316 in Participants With Familial Adenomatous Polyposis (FAP)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol